The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1487
Rolapitant (Varubi) for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting
The full article is available to subscribers Subscriber Login   

The FDA has approved rolapitant (Varubi – Tesaro), an oral substance P/neurokinin 1 (NK1) receptor antagonist, for use with other antiemetics to prevent delayed nausea and vomiting associated with cancer chemotherapy in adults. It is the third substance P/NK1 receptor antagonist to be approved in the US; aprepitant (Emend) and netupitant (only available in combination with the 5-HT3 receptor antagonist palonosetron as Akynzeo) were approved earlier for prevention of both acute and delayed chemotherapy-induced nausea and vomiting.1,2

STANDARD TREATMENT — Patients receiving moderately emetogenic chemotherapy should be treated with dexamethasone (Decadron, and generics) and the 5-HT3 receptor antagonist palonosetron (Aloxi); granisetron (Kytril, and others) or ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Rolapitant (Varubi) for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting
Article code: 1487c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian